VitaNova Life Sciences Corporation
VNOV
$2.38
$1.0072.46%
OTC PK
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -8.62% | 130.17% | 46.22% | -4.24% | 258.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -8.62% | 130.17% | 46.22% | -4.24% | 258.65% |
| Cost of Revenue | 91.03% | 230.50% | 22.01% | -0.57% | 312.33% |
| Gross Profit | -77.13% | 67.09% | 67.39% | -6.01% | 229.18% |
| SG&A Expenses | 398.67% | 235.32% | 73.39% | -14.67% | -36.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 117.57% | 232.45% | 42.88% | -11.44% | 179.22% |
| Operating Income | -110.15% | -57.12% | 58.47% | 28.63% | 365.11% |
| Income Before Tax | -109.90% | -56.88% | 63.32% | 28.63% | 364.22% |
| Income Tax Expenses | -144.40% | 158.07% | 125.98% | 41.84% | 332.05% |
| Earnings from Continuing Operations | -97.81% | -160.82% | 9.82% | 16.12% | 376.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -97.81% | -160.82% | 9.82% | 16.12% | 376.65% |
| EBIT | -110.15% | -57.12% | 58.47% | 28.63% | 365.11% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -97.81% | -160.23% | 10.26% | 15.15% | 377.61% |
| Normalized Basic EPS | -109.88% | -56.79% | 60.87% | 29.41% | 362.86% |
| EPS Diluted | -97.81% | -160.23% | 10.26% | 15.15% | 377.61% |
| Normalized Diluted EPS | -109.88% | -56.79% | 60.87% | 29.41% | 362.86% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |